NEW YORK (GenomeWeb) – Qiagen said today that its Artus T. vaginalis QS-RGQ kit has received CE marking and is now commercially available in Europe.
The real-time PCR assay is designed for the qualitative detection of Trichomonas vaginalis DNA purified from clinician-collected vaginal swabs, endocervical swabs, and urine samples from symptomatic and asymptomatic patients.
The test is configured for use with the QiaSymphony RGQ system, which comprises the QiaSymphony SP/AS (sample prep/assay setup) and Rotor-Gene Q instruments.
T. vaginalis is the most common curable sexually transmitted infection worldwide with 170 million to 190 million new cases each year, according to the World Health Organization. It is thought to be widely underdiagnosed due to a lack of routine testing and low sensitivity of the most commonly used microscopy-based diagnostic technique.
Artus T. vaginalis QS-RGQ provides "timely and sensitive detection of T. vaginalis in a wide range of sample types from both male and female patients," Michael Nugent, vice president and head of infection and immune diagnostics at Qiagen, said in a statement.